
LAROTRECTINIB (VITRAKVI®) IS RECOMMENDED AS A SYSTEMIC THERAPY OPTION FOR CERTAIN PATIENTS ACROSS 23 NTRKa GENE FUSION–POSITIVE TUMORS
VITRAKVI was approved based on a pooled efficacy analysis and not individual tumor types2
Guidelines included are current as of July 26, 2024. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org.
aCNS, central nervous system; NCCN, National Comprehensive Cancer Network® (NCCN®); NTRK, neurotrophic receptor tyrosine kinase.
bCategory 2A indicates a uniform NCCN consensus that the intervention is appropriate based upon lower-level evidence.1
cIncludes fallopian tube cancer and primary peritoneal cancer.1
INDICATION
VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
Select patients for therapy based on an FDA-approved test.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
References
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Biliary Tract Cancer V.3.2024, Breast Cancer V.4.2024, Central Nervous System Cancers V.2.2024, Cervical Cancer V.3.2024, Colon Cancer V.4.2024, Esophageal and Esophagogastric Junction Cancers V.3.2024, Gastric Cancer V.2.2024, Gastrointestinal Stromal Tumors (GISTs) V.1.2024, Head and Neck Cancers V.4.2024, Hepatocellular Carcinoma V.2.2024, Histiocytic Neoplasms V.2.2024, Melanoma: Cutaneous V.2.2024, Non-Small Cell Lung Cancer V.7.2024, Occult Primary V.2.2024, Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer V.3.2024, Pancreatic Adenocarcinoma V.2.2024, Pediatric Central Nervous System Cancers V.1.2024, Rectal Cancer V.3.2024, Small Bowel Adenocarcinoma V.4.2024, Soft Tissue Sarcoma V.1.2024, Thyroid Carcinoma V.3.2024, Uterine Neoplasms V.2.2024, and Vulvar Cancer V.4.2024. © 2024 National Comprehensive Cancer Network, Inc. All rights reserved. Accessed July 26, 2024. To view the most recent and complete version pf the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Return to content
- VITRAKVI [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; November 2023. Return to content